TI
ACHN

Telemetry Investments’s Achillion Pharmaceuticals ACHN Stock Holding History

Telemetry Investments’s Portfolio ACHN Stock Details ACHN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-48,305
Closed -$137K – 164
2018
Q2 		$137K Sell
48,305
-51,695
-52% -$176K 0.05% 118
2018
Q1 		$371K Sell
100,000
-35,000
-26% -$115K 0.14% 87
2017
Q4 		$389K Buy
+135,000
New +$490K 0.15% 81
2015
Q3 		– Sell
-65,000
Closed -$576K – 181
2015
Q2 		$576K Buy
65,000
+20,000
+44% +$189K 0.26% 72
2015
Q1 		$444K Buy
45,000
+5,000
+13% +$62.4K 0.25% 75
2014
Q4 		$490K Buy
+40,000
New +$488K 0.3% 77

Other funds holding ACHN

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Telemetry Investments's ACHN Position: Q3 2018 in Review

Telemetry Investments sold out of Achillion Pharmaceuticals (ACHN) in Q3 2018, closing a stake of 48,305 shares — an estimated $137K sold.

Telemetry Investments first reported a position in ACHN in Q4 2014 and held it in 6 quarters. The position peaked at $576K in Q2 2015. 137 funds tracked by Wall St. Rank hold ACHN as of Q3 2018.

  • Telemetry Investments reported no remaining Achillion Pharmaceuticals position as of Q3 2018 after selling out during the quarter.
  • Telemetry Investments sold 48,305 Achillion Pharmaceuticals shares in Q3 2018, an estimated $137K.
  • Telemetry Investments first reported a position in Achillion Pharmaceuticals in Q4 2014 and held it in 6 quarters.
  • Telemetry Investments's Achillion Pharmaceuticals position peaked at $576K in Q2 2015.
  • 137 funds tracked by Wall St. Rank held Achillion Pharmaceuticals as of Q3 2018.

Based on Telemetry Investments's 13F filing for Q3 2018, filed 14 Nov 2018.